Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effects of policosanol on lipid profile and cardiac events in older hypercholesterolaemic patients with coronary disease
Autore:
Mas, R; Castano, G; Fernandez, L; Illnait, J; Fernandez, J; Alvarez, E;
Indirizzi:
Natl Ctr Sci Res, Ctr Nat Prod, Havana, Cuba Natl Ctr Sci Res Havana Cuba tl Ctr Sci Res, Ctr Nat Prod, Havana, Cuba Med Surg Res Ctr, Havana, Cuba Med Surg Res Ctr Havana CubaMed Surg Res Ctr, Havana, Cuba
Titolo Testata:
CLINICAL DRUG INVESTIGATION
fascicolo: 7, volume: 21, anno: 2001,
pagine: 485 - 497
SICI:
1173-2563(2001)21:7<485:EOPOLP>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
EUROPEAN-ATHEROSCLEROSIS-SOCIETY; SUCCESSIVE DOSE INCREASES; SPRAGUE-DAWLEY RATS; II HYPERCHOLESTEROLEMIA; HEART-DISEASE; PLATELET-AGGREGATION; DENSITY-LIPOPROTEIN; HEALTHY-VOLUNTEERS; CHOLESTEROL LEVELS; CLINICAL-PRACTICE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
64
Recensione:
Indirizzi per estratti:
Indirizzo: Mas, R Natl Ctr Sci Res, Ctr Nat Prod, POB 6880 6990, Havana, Cuba Natl Ctr Sci Res POB 6880 6990 Havana Cuba 880 6990, Havana, Cuba
Citazione:
R. Mas et al., "Effects of policosanol on lipid profile and cardiac events in older hypercholesterolaemic patients with coronary disease", CLIN DRUG I, 21(7), 2001, pp. 485-497

Abstract

Objective: This study was undertaken to investigate the effects of policosanol administered for 1 year on the lipid profile and cardiac events of older hypercholesterolaemic patients with coronary heart disease (CHD). Patients: 280 older patients of both sexes with type II hypercholesterolaemia and CHD were included. Methods: Patients were randomised after 6 weeks of a standard step I cholesterol-lowering diet to treatment with policosanol (5mg) or placebo tabletsonce daily for I year. The starting dose was 5 mg/day, which was doubled to 10 mg/day if predefined goals were not reached after 6 months on therapy. Cardiac events were defined as death from cardiovascular causes [fatal myocardial infarction (MI), sudden cardiac death] and nonfatal Ml, unstable angina pectoris or coronary surgery. Results: Policosanol significantly (p < 0.00001) lowered serum low-densitylipoprotein-cholesterol (LDL-C) [21.3%], total cholesterol (TC) [15.9%], TC to high-density lipoprotein-cholesterol (HDL-C) ratio [22.7%] and LDL-C/HDL-C ratio (26.1%), as well as triglycerides (7.8%, p < 0.001). HDL-C was significantly increased (18.2%, p < 0.001). The frequency of cardiac events was lower (p < 0.001) in policosanol (1 event, 0.7%) than in placebo (11 events, 7.9%) recipients. Likewise, the frequency of all vascular serious adverse events (four events, 2.9%) and all-cause hospitalisations in the policosanol group (five events, 3.6%) was lower (p < 0.001) than in the placebo group (15 and 20 events, 10.7 and 14.3%, respectively). No patient died during the study. Policosanol was well tolerated. Conclusions: Long-term policosanol is effective in lowering LDL-C and TC and in increasing HDL-C levels in older patients with CHD, and also showed benefits in the occurrence of cardiac events and overall frequency of serious adverse events of vascular aetiology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/04/20 alle ore 21:48:40